Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 42,046 | 56,376 | 40,005 | 55,706 | 48,714 |
| Cost of Goods | 18,009 | 17,284 | 20,189 | -2,657 | 38,281 |
| Gross Profit | 24,037 | 39,092 | 19,816 | 58,363 | 10,433 |
| Operating Expenses | 37,082 | 48,372 | 45,602 | 63,662 | 61,119 |
| Operating Income | -13,036 | -8,996 | -25,597 | -5,956 | -50,405 |
| Interest Expense | 1,410 | 1,642 | 1,561 | 1,636 | 3,952 |
| Other Income | -43 | -534 | 282 | 434 | 261 |
| Pre-tax Income | -14,489 | -11,172 | -26,876 | -7,158 | -54,096 |
| Net Income Continuous | -14,489 | -11,172 | -26,876 | -7,158 | -54,096 |
| Net Income | $-14,489 | $-11,172 | $-26,876 | $-7,158 | $-54,096 |
| EPS Basic Total Ops | -0.08 | -0.06 | -0.15 | -0.04 | -0.29 |
| EPS Basic Continuous Ops | -0.08 | -0.06 | -0.15 | -0.03 | -0.29 |
| EPS Diluted Total Ops | -0.08 | -0.06 | -0.15 | -0.03 | -0.29 |
| EPS Diluted Continuous Ops | -0.08 | -0.06 | -0.15 | -0.03 | -0.29 |
| EBITDA(a) | $-3,629 | $411 | $-16,188 | $3,463 | $-40,981 |